---
id: vaccine-platforms-and-antimicrobials
name: Vaccine Platforms & Antimicrobials
family: technological
tier: active
url: https://explorer.talin.digital/e/vaccine-platforms-and-antimicrobials/
author: Benjamin Talin
citation: Talin, B. (2026). The Future Explorer. https://explorer.talin.digital (dataset v0.4.0, 2026-11-16)
license: CC-BY-NC-4.0
---

# Vaccine Platforms & Antimicrobials

Two defences against germs. Vaccine platforms are ready-made methods, such as mRNA, that turn a new virus's genetic code into a vaccine quickly; one went from an unknown virus to full approval in under two years. Antimicrobials are the medicines that kill bacteria, and here progress is thin: in about eight years only two genuinely new classes of antibiotic were approved anywhere. Same science base, opposite economics, because new antibiotics are kept in reserve and earn little.

> Two defences against the same threat: platforms that turn a pathogen sequence into a vaccine quickly, and the search for new classes of antibiotic.

## Maturity
3/5 — Vaccine platforms are demonstrably mature and delivered at scale; the antimicrobial half is a market failure with a thin pipeline. Of 90 antibacterials in clinical development, 15 are innovative and 5 work against a WHO critical pathogen. Seventeen have been authorised since mid-2017 and two are a new chemical class.

Capability 4 · deployment 3 · absorption 3 · bound by incentives · flat

Source: WHO, Analysis of antibacterial agents in clinical and preclinical development (2 Oct 2025, data to 15 Feb 2025); WHO Global Vaccine Market Report 2025 (Dec 2025); WHO/UNICEF immunisation estimates (15 Jul 2026); NHS England/NICE antimicrobial subscription model (12 Aug 2024). Post-approval insolvencies kept from the seed: Achaogen Ch.11 Apr 2019, Aradigm Feb 2019, Melinta Dec 2019 (2024–2026)

## What it is
Rapid-response vaccine technologies and the development of new classes of antibiotic and antimicrobial agent.

## What it does
It is the enabler standing between a pathogen and a pandemic, and between antimicrobial resistance and a return to pre-antibiotic medicine. Its two halves are moving in opposite directions.

## Common misconception
That vaccine platform success implies antimicrobial success. Vaccines had a demonstrated pandemic response; the antibiotic pipeline is nearly empty, and for market reasons rather than scientific ones.

## Steepens
- Zoonotic and Antimicrobial Resistance Risk (zoonotic-and-antimicrobial-resistance-risk) — large
- Longevity and the Healthspan Gap (longevity-and-the-healthspan-gap) — moderate
- Food System Transformation (food-system-transformation) — moderate

## What would change its gradient
- Pull incentives - subscription or market-entry rewards that decouple revenue from volume
- Stewardship, which reduces resistance pressure and cuts revenue further
- Surveillance capacity, which determines how early anything is seen
